[{"orgOrder":0,"company":"Nutriband","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"4","companyTruncated":"Nutriband \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Nutriband

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Nutriband is partnering with Kindeva to develop Aversa Fentanyl which combines Nutriband’s Aversa abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch.

                          Product Name : Aversa Fentanyl

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          February 13, 2025

                          Lead Product(s) : Fentanyl

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Kindeva Drug Delivery

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Aversa fentanyl abuse-deterrent transdermal technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, & accidental exposure of drugs.

                          Product Name : Aversa

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          June 20, 2024

                          Lead Product(s) : Fentanyl

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Net proceeds will fund the development of AVERSA Fentanyl, a potential first abuse-deterrent opioid patch to reduce misuse and accidental exposure risks with transdermal fentanyl.

                          Product Name : Aversa

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          April 24, 2024

                          Lead Product(s) : Fentanyl

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : $8.4 million

                          Deal Type : Private Placement

                          blank

                          04

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The primary use of proceeds will be for completing the remaining clinical development of AVERSA Fentanyl and submission of its NDA with the FDA for marketing approval.

                          Product Name : Aversa

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          April 19, 2024

                          Lead Product(s) : Fentanyl

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : $8.4 million

                          Deal Type : Private Placement

                          blank

                          05

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Aversa (fentanyl) utilizes abuse-deterrent transdermal technology with aversive agents to prevent drug abuse, diversion, and accidental exposure.

                          Product Name : Aversa

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          March 27, 2024

                          Lead Product(s) : Fentanyl

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The net proceeds will be used to fund the development and regulatory submission process for the Company's patented lead product platform, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system.

                          Product Name : Aversa

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          July 14, 2023

                          Lead Product(s) : Fentanyl

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          07

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : AVERSA™ (fentanyl) combines Nutriband’s proprietary AVERSA™ abuse-deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch system.

                          Product Name : Aversa

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          April 04, 2023

                          Lead Product(s) : Fentanyl

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Kindeva Drug Delivery

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The financing will be used for commercialising AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. AVERSA™ Fentanyl contains Nutriband's proprietary transdermal abuse deterrent technology.

                          Product Name : Aversa

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          March 28, 2023

                          Lead Product(s) : Fentanyl

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          09

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Aversa (fentanyl) abuse deterrent technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential such as opioids used to treat moderate to s...

                          Product Name : Aversa

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          January 12, 2022

                          Lead Product(s) : Fentanyl

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Aversa (fentanyl) is an abuse deterrent transdermal technology that incorporates aversive agents to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential, specifically opioids.

                          Product Name : Aversa

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          January 08, 2022

                          Lead Product(s) : Fentanyl

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank